Form 4: Guardant Health Chief Technology Officer Reports Stock Transactions

Darya Chudova, Chief Technology Officer of Guardant Health, reported the acquisition and disposal of company stock and restricted stock units on December 1, 2024.

Summary

• Darya Chudova, the Chief Technology Officer of Guardant Health, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On December 1, 2024, she acquired 316 shares of common stock through the vesting of restricted stock units.
• Also on December 1, 2024, 161 shares were disposed of to cover tax withholding obligations related to the vesting of the restricted stock units.
• Following these transactions, Ms. Chudova directly owns 54,780 shares of Guardant Health common stock and 947 restricted stock units.
• The restricted stock units were granted on November 2, 2021, and vest in equal quarterly installments, with full vesting expected by September 1, 2025.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions, which are neither particularly positive nor negative. The transactions are expected and do not indicate any significant change in the company's outlook.

Positives

• The vesting of restricted stock units indicates continued alignment of the executive's interests with the company's performance.
• The acquisition of 316 shares increases the executive's direct ownership in the company.

Negatives

• The disposal of 161 shares, while for tax purposes, slightly reduces the executive's overall shareholding.

Risks

• The sale of shares to cover tax obligations could be perceived negatively by some investors, although it is a common practice.
• Changes in executive ownership can sometimes lead to speculation about the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the ownership changes of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The vesting schedule of the restricted stock units is typical for executive compensation packages in the tech and biotech industries.
• The tax withholding process is a common practice when restricted stock units vest.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
• The filing provides transparency to stakeholders regarding executive ownership.

Key Dates

Keywords

Guardant Health, Darya Chudova, Form 4, stock transaction, restricted stock units, executive ownership, insider trading